SuviCa Inc.
The University of Colorado Connection
SuviCa is a CU Boulder start-up cofounded by Tin Tin Su (CU Boulder Molecular, Cellular & Developmental Biology) focused on the discovery and development of small molecule cancer therapeutics targeting a unique mechanism of action. Based on the compelling efficacy and safety profiles of SuViCa’s lead drug candidate, SVC112, SuViCa has entered the competitive National Cancer Institute Experimental Therapeutics (NExT) Program to develop SVC112 for salivary gland cancer (SGC). SVC112 has been developed in collaboration between Tin Tin Su and Antonio Jimeno (CU Anschutz Medicine-Medical Oncology), and further development of SVC112 is being supported by the Anschutz Acceleration Initiative.
Funding Status and Investment Opportunities
- Industry Applications: Health and Wellness, Biotech, Therapeutics
- Funding Stage: Seed Round
- Contact for Investment Inquiries: Tin Tin Su, tin.su@Colorado.edu
In the News
Venture Partners Programs
- Destination Startup (2024)
- Lab Venture Challenge (2018)
- Intellectual Property Management (2003)
Technology Development Funding
U.S. National Institutes of Health (NIH)
This page was last updated on April 11, 2025. Please email vpnews@colorado.edu for corrections or updates
The Insider Investor E-Newsletter
Media Inquiries
For marketing and communication inquiries, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit colorado.edu/news/formedia.